Vaccine Clinical Trial Oxford University “Promising Results” 6:21, July 21
k10012525451_202007210633_202007210640.mp4
The University of Oxford in the UK has confirmed that the amount of "antibody" that plays a role in immunity increases after vaccination, as a result of clinical trials in humans regarding a new coronavirus vaccine being developed with a pharmaceutical company. We summarized the research results of the initial stage.
Oxford University is working on the development of a new coronavirus vaccine with pharmaceutical giants AstraZeneca and the results of the initial stage of three clinical trials were published in the British medical journal “Lancet” on the 20th.
According to it, when the amount of the antibody was examined in 127 of the vaccinated people, the amount of the antibody was higher than that in the unvaccinated person, and it was confirmed that it was the highest 28 days after the vaccination. about it.
In addition, the amount of antibody remained high even 56 days after vaccination, and when 35 more people were examined, "neutralizing antibody" that weakens the function of the virus was confirmed in more than 90% of the people. about it.
On the other hand, 70% of the vaccinated people complained of headache and fatigue.
The development team stated that "there was no serious health effect," and continued clinical trials to confirm the safety and efficacy in humans, saying "the results are promising."
In addition, the same medical journal also published the results of a second-stage clinical trial that confirmed the production of antibodies and the safety of one of the vaccines under development in China.
Prime Minister Johnson "an important step"
British Prime Minister Johnson posted a welcome comment on Twitter, "It's very positive news. There is no guarantee yet, but it's an important step in the right direction."
Oxford University and others are developing a type called "viral vector vaccine". The British government has already secured a supply of 100 million times, but on the 20th, in addition to this,
▽ Germany Announced that it has secured
a
total of 90 million doses of "RNA vaccine" being developed by other pharmaceutical companies and "Inactivated vaccine" being developed by a French pharmaceutical company .
The British government says it has the opportunity to get vaccines quickly by securing three different types of vaccines, and there is likely to be more fierce competition between nations over securing vaccines.
WHO "The challenge is to secure sufficient production"
Ryan, who is in charge of crisis response at the World Health Organization (WHO), said at a regular press conference yesterday, "We welcome the research and congratulate our colleagues in the Oxford University research group. It's just a staged trial."
"The challenge is to ensure enough production to meet the needs of the world when the vaccine proves effective," Ryan said, adding that production is limited. He stressed the idea that countries need to work together to get the vaccine to people.